Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day

by NASDAQ Market News December 5, 2019

NASDAQ Market News
Click here to email author

Arecor Announces Positive Headline Results for the First Phase I Clinical Trial of AT247, a Novel Ultra Rapid Acting Formulation of Insulin

Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan

Ads